2024 Round Table Sessions

Initiated in 2015, the Round Table Discussions are a core feature of the CGC Annual Meeting. This format allows attendees to gather in a small group to discuss current practices in clinical genomics, emerging technologies, and critical concepts that affect clinical laboratory operations.     

On Tuesday, August 6, CGC 2024 will feature these small breakout sessions for in-person attendees. As you register for the meeting, please select your desired topic. There is a limit of 12 people for each topic.                                         


2024 Round Table Sessions include the following topics from which participants may choose during registration:

  1. Implications of FDA’s proposed rule regarding laboratory developed tests (LDT)  

  2. Clinical applications and guideline updates for liquid biopsy

  3. Cancer pharmacogenomics: genomic alterations and germline variance in cancer drug resistance

  4. Artificial Intelligence (AI) and Machine Learning (ML) in clinical genomics

  5. Innovations in genomic technologies for low-resource settings

  6. Laboratory automation and changes in testing practices to address laboratory workforce challenges and Workforce readiness for cancer genomic laboratories

  7. Implications and solutions for clinical cancer genomics from racial and ancestral disparity in genomic data and research

  8. Complex structural rearrangement analysis with novel technologies 

  9. The clinical application of whole genome/exome sequencing (WGS/WES) and long read sequencing (LRS)

  10. Molecular-based classification of hematologic malignancy

  11. Clinical utility of measurable residual disease (MRD) monitoring for hematopoietic neoplasms  

  12. Validation of bioinformatic pipelines

  13. Integration of molecular and cytogenetic laboratories

  14. DNA methylation (and gene expression) profiling for molecular subtyping

  15. Cytogenetic workup strategy in the era of new genomic tools

  16. Germline and somatic variant classification in cancers and clinical use of the ClinGen/CGC/VICC oncogenicity guideline in practice 

  17. Bioinformatics and data interoperability of clinical cancer genomics